Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Loredana Mrak"'
Autor:
Martina Vrankar, Nina Boc, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But Hadžić, Anton Crnjac, Marina Čakš, Dominik Časar, Eva Ćirić, Tanja Čufer, Ana Demšar, Rok Devjak, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik Kramberger, Maja Ivanetič Pantar, Marija Ivanovič, Urška Janžič, Staša Jelerčič, Veronika Kloboves Prevodnik, Mile Kovačevič, Luka Ležaić, Mateja Marc Malovrh, Katja Mohorčič, Loredana Mrak, Igor Požek, Nina Turnšek, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačič, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar
Publikováno v:
Onkologija, Vol 27, Iss 1 (2023)
In 2019, the Recommendations for the management of patients with lung cancer were published bringing much-needed standardisation of diagnosis and treatment to improve survival of patients with lung cancer. Three years after the original Recommendatio
Externí odkaz:
https://doaj.org/article/3b1270e9772f48a88ef104c12d74f549
Autor:
Urska Janzic, Urska Bidovec-Stojkovic, Peter Korosec, Katja Mohorcic, Loredana Mrak, Marina Caks, Maja Ravnik, Erik Skof, Matija Rijavec
Publikováno v:
Vaccines, Vol 11, Iss 6, p 1017 (2023)
Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of
Externí odkaz:
https://doaj.org/article/261d440f6a5543cb8bf49f92756fe42e
Autor:
Urska Janzic, Urska Bidovec-Stojkovic, Katja Mohorcic, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanovic, Maja Ravnik, Marina Caks, Erik Skof, Jerneja Debeljak, Peter Korosec, Matija Rijavec
Publikováno v:
Future oncology, pp. 1-10, 2022.
Because cancer patients are especially endangered by SARS-CoV-2 infection and have worse disease course and outcomes, it is crucial to protect them from this infection. This study was aimed at assessing protective antibodies after patients received m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d509e621dcca3de6ff9855bdd027b91
https://dirros.openscience.si/IzpisGradiva.php?id=15227
https://dirros.openscience.si/IzpisGradiva.php?id=15227
Autor:
Urska Janzic, Urska Bidovec-Stojkovic, Katja Mohorcic, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanovic, Maja Ravnik, Marina Caks, Erik Skof, Jerneja Debeljak, Peter Korosec, Matija Rijavec
Background: SARS-CoV-2 vaccination in cancer patients is crucial since they are at increased risk of severe COVID-19 disease course, but data on efficacy and safety of vaccination are scarce.Methods: We performed a prospective observational study of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::102e25335e4e4c0e321d67133f6416e7
https://doi.org/10.21203/rs.3.rs-1185527/v1
https://doi.org/10.21203/rs.3.rs-1185527/v1